Date: 2012-12-11
Type of information: Development agreement
Compound: XEN402
Company: Teva Pharmaceutical Industries (Israel) Xenon Pharmaceuticals (USA)
Therapeutic area: CNS diseases
Type agreement: development
licensing
Action mechanism: XEN402 is an oral sodium channel inhibitor. It treats pain locally at its source through blocking of Nav1.7 and Nav1.8 sodium channels.
Disease: painful disorders, pain
Details: Teva Pharmaceutical Industries and Xenon Pharmaceuticals have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a variety of painful disorders. This product specifically targets sodium channels which are abundantly found in sensory nerve endings that can increase in chronic painful conditions. In addition, XEN402 has the potential for broader therapeutic use across other pain conditions.
The product has been studied in human subjects as both oral and topical forms. In a published study, oral XEN402 was shown to be effective at relieving the pain associated with the rare neuropathic pain condition, erythromelalgia (Pain 2012 Jan;153(1):80-5). Topical XEN402 was studied in a phase 2 trial to evaluate for effectiveness in alleviating the pain of post herpetic neuralgia. In this study the proportion of patients reporting clinically meaningful reductions in pain was significantly greater for topical XEN402 than for placebo (p=0.049 for >30% response and p=0.0078 for >50% response).
Financial terms: Under the agreement, Teva will pay Xenon an upfront fee of $41 million. In addition Teva shall pay development, regulatory, and sales-based milestones totaling up to $335 million. Xenon is entitled to royalties payable on sales and an option to participate in commercialization in the U.S.
Latest news:
